Antoine Girard

Dr. Antoine Girard

1. Department of Nuclear Medicine, Centre Eugène Marquis, Université Rennes 1, 35000 Rennes, France.
+1
orcid

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 January 2019 in European Radiology
Verified
Journal Article
Closed access
PDF file
AGAntoine Girard
Antoine Girard
MRMathieu Rouanne
Mathieu Rouanne
STSarah Taconet
Sarah Taconet
CRCamélia Radulescu
Camélia Radulescu
YNYann Neuzillet
Yann Neuzillet
JGJean-François Grellier
Jean-François Grellier

1 January 2023 in Radiology
Verified
Journal Article
Closed access
Laurent DercleLaurent Dercle
Laurent Dercle
SSShawn Sun
Shawn Sun
RSRomain David Seban
Romain David Seban
AMAhmed Mekki
Ahmed Mekki
RSRoger Sun
Roger Sun
LSLawrence H. Schwartz
Lawrence H. Schwartz
This review highlights the distinct imaging patterns associated with immunotherapy response and progression and considers novel imaging approaches to evaluate emerging immunotherapies. Criteria based on measurements of lesion diameter at CT have guided treatment with historical therapies due to the strong association between tumor size and survival. Clinical experience with immun...

1 March 2019 in Bulletin du Cancer
Verified
Journal Article
Closed access
PSPierre-Yves Salaün
Pierre-Yves Salaün
RARonan Abgral
Ronan Abgral
Olivier MalardOlivier Malard
Olivier Malard
SQSolène Querellou-Lefranc
Solène Querellou-Lefranc
GQGilles Quere
Gilles Quere
FCFlorent Cachin
Florent Cachin

Verified
Journal Article
Open access
PDF file
JMJeremy McGale
Jeremy McGale
SKSakshi Khurana
Sakshi Khurana
AHAlice Huang
Alice Huang
TRTina Roa
Tina Roa
RYRandy Yeh
Randy Yeh
RSRomain David Seban
Romain David Seban
HER2 (Human Epidermal Growth Factor Receptor 2)-positive breast cancer is characterized by amplification of the HER2 gene and is associated with more aggressive tumor growth, increased risk of metastasis, and poorer prognosis when compared to other subtypes of breast cancer. HER2 expression is therefore a critical tumor feature that can be used to diagnose and treat breast cancer. Moving forward, advances in HER2 in vivo imaging, involving the use of techniques such as positron emission tomography (PET) and single-photon emission computed tomography (SPECT), may allow for a greater role for HER2 status in guiding the management of breast cancer patients. This will apply both to patients who are HER2-positive and those who have limited-to-minimal immunohistochemical HER2 expression (HER2-low), with imaging ultimately helping clinicians determine the size and location of tumors. Additionally, PET and SPECT could help evaluate effectiveness of HER2-targeted therapies, such as trastuzumab or pertuzumab for HER2-positive cancers, and specially modified antibody drug conjugates (ADC), such as trastuzumab-deruxtecan, for HER2-low variants. This review will explore the current and future role of HER2 imaging in personalizing the care of patients diagnosed with breast cancer.

10 February 2022 in Cancers
Verified
Journal Article
Open access
PDF file
Jules Zhang-YinJules Zhang-Yin
Jules Zhang-Yin
AGAntoine Girard
Antoine Girard
MBMarc Bertaux
Marc Bertaux
PET imaging is being increasingly used to supplement MRI in the clinical management of brain tumors. The main radiotracers implemented in clinical practice include [18F]FDG, radiolabeled amino acids ([11C]MET, [18F]FDOPA, [18F]FET) and [68Ga]Ga-DOTA-SSTR, targeting glucose metabolism, L-amino-acid transport and somatostatin receptors expression, respectively. This review aims at addressing the current place and perspectives of brain PET imaging for patients who suffer from primary or secondary brain tumors, at diagnosis and during follow-up. A special focus is given to the following: radiolabeled amino acids PET imaging for tumor characterization and follow-up in gliomas; the role of amino acid PET and [18F]FDG PET for detecting brain metastases recurrence; [68Ga]Ga-DOTA-SSTR PET for guiding treatment in meningioma and particularly before targeted radiotherapy.

6 October 2020 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
AGAntoine Girard
Antoine Girard
HRHelena Vila Reyes
Helena Vila Reyes
HSHiram Shaish
Hiram Shaish
JGJean-François Grellier
Jean-François Grellier
LDLaurent Dercle
Laurent Dercle
MRMathieu Rouanne
Mathieu Rouanne
Bladder cancer (BC) is the 10th most common cancer worldwide. Approximately one quarter of patients with BC have muscle-invasive disease (MIBC). Muscle-invasive disease carries a poor prognosis and choosing the optimal treatment option is critical to improve patients’ outcomes. Ongoing research supports the role of 2-deoxy-2-(18F)fluoro-D-glucose positron emission tomography (18F-FDG PET) in guiding patient-specific management decisions throughout the course of MIBC. As an imaging modality, 18F-FDG PET is acquired simultaneously with either computed tomography (CT) or MRI to offer a hybrid approach combining anatomical and metabolic information that complement each other. At initial staging, 18F-FDG PET/CT enhances the detection of extravesical disease, particularly in patients classified as oligometastatic by conventional imaging. 18F-FDG PET/CT has value in monitoring response to neoadjuvant and systemic chemotherapy, as well as in localizing relapse after treatment. In the new era of immunotherapy, 18F-FDG PET/CT may also be useful to monitor treatment efficacy as well as to detect immune-related adverse events. With the advent of artificial intelligence techniques such as radiomics and deep learning, these hybrid medical images can be mined for quantitative data, providing incremental value over current standard-of-care clinical and biological data. This approach has the potential to produce a major paradigm shift toward data-driven precision medicine with the ultimate goal of personalized medicine. In this review, we highlight current literature reporting the role of 18F-FDG PET in supporting personalized management decisions for patients with MIBC. Specific topics reviewed include the incremental value of 18F-FDG PET in prognostication, pre-operative planning, response assessment, prediction of recurrence, and diagnosing drug toxicity.